epigenetic target inhibitors (Ryvu Therapeutics)

N/A

Report date: 2025/03/20 15:33:22
NME

Base Information

Drug Nameepigenetic target inhibitors (Ryvu Therapeutics)
Drug Alias NameSMARCA2/BRM protein inhibitor (Selvita)SMARCA2/BRM protein inhibitor (Ryvu Therapeutics)epigenetic target inhibitors (Selvita)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProbable global transcription activator SNF2L2 inhibitors
TargetsProbable global transcription activator SNF2L2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPoland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A